| Donald C Rice Optometrist Inc | |
| 1320 W Main St, Duncan, Oklahoma 73533 | |
| (580) 255-0988 |
| Name | Donald C Rice Optometrist Inc |
|---|---|
| Organization Name | Dr. Donald C Rice Optometrist Inc |
| Location | 1320 W Main St, Duncan, Oklahoma 73533 |
| Type | Supplier |
| Phone | (580) 255-0988 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
"The health ministry has formed a committee to frame a policy for antibiotic use, following an uproar over a Lancet study that traced a drug-resistant bacterial superbug's origins to India," LiveMint.com reports. The panel will also look into the "excessive use of antibiotics among Indians," partly fueled by self-medication, that has increased resistance to the drugs. The article notes that the Indian government "rejected the findings of the report" but has "taken note of a lack of policy on antibiotics" (Pandeya, 9/3).
People who relied on conservative media or social media in the early days of the COVID-19 outbreak were more likely to be misinformed about how to prevent the virus and believe conspiracy theories about it, a study of media use and public knowledge has found.
Resective surgery is an effective treatment for dug-resistant epilepsy. To investigate the effect of epilepsy surgery on patients lives, researchers from the Comprehensive Epilepsy Program at the Henry Ford Hospital in Detroit conducted a long-term retrospective follow up of surgical patients and correlated post-surgical psychosocial outcomes with seizure outcome and brain area surgically treated.
Forest Laboratories announced today its agreement to acquire additional rights to NXL 104, which amends the terms of its prior agreement with Novexel covering the combination of NXL 104 with ceftaroline and adds additional rights to the combination of ceftazidime and NXL 104, through a transaction with AstraZeneca executed immediately following AstraZeneca's announced acquisition of Novexel, S.A.
Oncothyreon Inc. today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux®). PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.
› Verified 8 days ago
News Archive
"The health ministry has formed a committee to frame a policy for antibiotic use, following an uproar over a Lancet study that traced a drug-resistant bacterial superbug's origins to India," LiveMint.com reports. The panel will also look into the "excessive use of antibiotics among Indians," partly fueled by self-medication, that has increased resistance to the drugs. The article notes that the Indian government "rejected the findings of the report" but has "taken note of a lack of policy on antibiotics" (Pandeya, 9/3).
People who relied on conservative media or social media in the early days of the COVID-19 outbreak were more likely to be misinformed about how to prevent the virus and believe conspiracy theories about it, a study of media use and public knowledge has found.
Resective surgery is an effective treatment for dug-resistant epilepsy. To investigate the effect of epilepsy surgery on patients lives, researchers from the Comprehensive Epilepsy Program at the Henry Ford Hospital in Detroit conducted a long-term retrospective follow up of surgical patients and correlated post-surgical psychosocial outcomes with seizure outcome and brain area surgically treated.
Forest Laboratories announced today its agreement to acquire additional rights to NXL 104, which amends the terms of its prior agreement with Novexel covering the combination of NXL 104 with ceftaroline and adds additional rights to the combination of ceftazidime and NXL 104, through a transaction with AstraZeneca executed immediately following AstraZeneca's announced acquisition of Novexel, S.A.
Oncothyreon Inc. today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux®). PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.
› Verified 8 days ago
Cvs Pharmacy #10274 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1520 W Elk Ave, Duncan, Oklahoma 73533 Phone: (580) 470-8857 | |
Walgreens #5142 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1100 N Highway 81, Duncan, Oklahoma 73533 Phone: (580) 252-2375 | |
Walmart Pharmacy 10-1160 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 3393 N 81 Hwy, Duncan, Oklahoma 73533 Phone: (580) 252-4888 | |
Baker Express Pharmacy Type: Durable Medical Equipment & Medical Supplies Supplier Location: 3344 N Hwy 81, Duncan, Oklahoma 73533 Phone: (580) 255-3784 | |
R&s Drug Store #3 Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 3117 N Highway 81, Duncan, Oklahoma 73533 Phone: (580) 252-0140 |